Clinical Trials Logo

Papillomavirus Infections clinical trials

View clinical trials related to Papillomavirus Infections.

Filter by:

NCT ID: NCT02067507 Completed - Clinical trials for Human Papilloma Virus Infection

Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Start date: June 2012
Phase: N/A
Study type: Interventional

The primary aim of the project is to increase human papillomavirus (HPV) vaccine receipt rates among low-income, ethnic minority adolescents (girls and boys 11-17 years of age) in Los Angeles County. We will accomplish this goal by implementing and rigorously evaluating interventions in multiple venues that serve our target population, including the Los Angeles County Department of Public Health (LACDPH) and two large Federally Qualified Health Centers (FQHCs). Our hypotheses are: Primary hypothesis: 1. The intervention group will have a higher rate of HPV vaccine initiation at follow-up compared to the control group. Secondary hypothesis: 2. The intervention group will have higher vaccine completion rates (3 doses) at follow-up compared to the control group.

NCT ID: NCT02065973 Completed - Clinical trials for High-risk HPV Infection and Biopsy-proven CIN1

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

Start date: February 2014
Phase: Phase 1
Study type: Interventional

Phase I, open-label, sequential-cohort, ascending multiple-dose study to evaluate the safety and tolerability of escalating doses of PDS0101 in female subjects with high-risk HPV infection and biopsy-proven CIN1. The study will include 3 cohorts of 3 to 6 subjects each based on a modified "3 + 3" dose-escalation study design. The study will be initiated with Cohort 1 and progress through Cohort 3, with each subsequent cohort receiving a higher dose of PDS0101. Successive cohorts will receive a constant dose of HPV-16 E6 and E7 peptides. All subjects will receive 3 vaccinations SC given approximately 21 days apart. Dosing and dose escalation will be based on safety evaluation for determination of potential dose-limiting toxicity (DLT).

NCT ID: NCT02048020 Completed - Clinical trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Start date: December 26, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well paclitaxel and carboplatin before radiation therapy with paclitaxel works in treating human papillomavirus (HPV)-positive patients with stage III-IV oropharynx, hypopharynx, or larynx cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving paclitaxel and carboplatin before radiation therapy with paclitaxel may kill more tumor cells.

NCT ID: NCT02009800 Completed - Clinical trials for Human Papillomavirus Infections

ICI-VPH: Impact of HPV Immunisation Schedules Against HPV

ICI-VPH
Start date: November 2013
Phase: Phase 3
Study type: Interventional

This randomised clinical trial aims to determine whether an immunization schedule comprising two doses of Gardasil administered six months apart is non-inferior to a schedule comprising three doses administered at 0, 6 and 60 months for the prevention of HPV-16 and HPV-18 infections that persist for at least six months, up to ten years after the initial vaccination. The study hypothesis is that the two-dose schedule would offer similar protection as that of a three-dose schedule against persistent HPV-16/18 infections.

NCT ID: NCT02003508 Completed - Clinical trials for Human Papillomavirus

Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination

Impress
Start date: January 2014
Phase:
Study type: Observational

This study will examine how common HPV infection is in teenage males in Australia before and after the introduction of universal school based vaccination of males in Australia.

NCT ID: NCT01984697 Completed - Clinical trials for Human Papillomavirus Infection

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Start date: December 12, 2013
Phase: Phase 3
Study type: Interventional

This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal was to establish that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who received the standard 3-dose regimen of V503 (i.e., the population and dose regimen used to establish V503 efficacy).

NCT ID: NCT01946139 Completed - HIV Infection Clinical Trials

Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV

Start date: December 4, 2013
Phase: N/A
Study type: Interventional

This clinical trial studies anal human papillomavirus (HPV) tests in screening for cell changes in the anus in patients with human immunodeficiency virus (HIV). Screening tests may help doctors find cancer cells early and plan better treatment for anal cancer. Completing multiple screening tests may help find the best method for detecting cell changes in the anus.

NCT ID: NCT01932697 Completed - Clinical trials for Human Papillomavirus Infection

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

Start date: September 4, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy with docetaxel my kill more tumor cells.

NCT ID: NCT01924117 Completed - Clinical trials for Intraepithelial Neoplasia

Genotypification and Predisposing Factors in Human Papilloma Virus Infection

HPV
Start date: February 2011
Phase: N/A
Study type: Interventional

Objective: Determine the genotypes and risk factors associated with human papilloma virus infection in Mexican women. Methods: It was a cross-sectional study of women attended at the Materno-Perinatal Hospital "Mónica Pretelini" and the Medical Research Center (CICMED), who were asked to complete a risk factor questionnaire and submitted to colposcopy to identify SIL. Cervical swab samples were obtained to perform linear array HPV genotyping test (Roche®, Mannheim, Germany).

NCT ID: NCT01894425 Completed - Infertility Clinical Trials

Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation

PAPILLO-PMA
Start date: May 2014
Phase: N/A
Study type: Observational

The main objective of this study is to investigate the association between the presence of HPV infection in one or both members of infertile/sub-infertile couples and the outcome of pregnancies obtained by assisted reproduction. The success of assisted medical procreation is defined as achieving a pregnancy resulting in the birth of a living, viable child.